BACKGROUND: Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate. OBJECTIVE: To evaluate the effect of AAT on IPF progression in pirfenidone-treated patients. METHODS: This post hoc analysis included patients with IPF who received pirfenidone in 3 trials (CAPACITY [PIPF-004/PIPF-006] and ASCEND [PIPF-016]). Pulmonary function, exercise tolerance, survival, hospitalizations, and adverse events (AEs) over 52 weeks were analyzed by baseline AAT use. Disease progression was defined as a decrease in forced vital capacity (FVC) of ≥10%, a decrease in 6-min walking distance of ≥50 m, or death over 1 year. RESULTS: Of 623 patients, 44% received AAT. No significant differences were found at 52 weeks (AAT versus non-AAT, respectively) in disease progression (24.9 vs. 30.6%; p = 0.12), all-cause mortality rate (2.9 vs. 4.0%; p = 0.47), IPF-related mortality rate (1.1 vs. 2.0%; p = 0.37), all-cause hospitalization rate (16.1 vs. 18.3%; p = 0.48), or mean change in percent FVC (-2.7 vs. -3.1%; p = 0.44). A relative, but not absolute, FVC decline of ≥10% favored AAT (15 vs. 22%; p = 0.03). Severe gastrointestinal AEs (3.7 vs. 0.9%; p = 0.015) and severe pulmonary infections (3.7 vs. 1.1%; p = 0.035) were more frequent with AAT. CONCLUSIONS: AAT and pirfenidone had outcomes comparable to those of pirfenidone alone in patients with IPF, underscoring the need for prospective trials to elucidate the role of AAT with or without antifibrotic drugs as a treatment for IPF.
BACKGROUND:Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate. OBJECTIVE: To evaluate the effect of AAT on IPF progression in pirfenidone-treated patients. METHODS: This post hoc analysis included patients with IPF who received pirfenidone in 3 trials (CAPACITY [PIPF-004/PIPF-006] and ASCEND [PIPF-016]). Pulmonary function, exercise tolerance, survival, hospitalizations, and adverse events (AEs) over 52 weeks were analyzed by baseline AAT use. Disease progression was defined as a decrease in forced vital capacity (FVC) of ≥10%, a decrease in 6-min walking distance of ≥50 m, or death over 1 year. RESULTS: Of 623 patients, 44% received AAT. No significant differences were found at 52 weeks (AAT versus non-AAT, respectively) in disease progression (24.9 vs. 30.6%; p = 0.12), all-cause mortality rate (2.9 vs. 4.0%; p = 0.47), IPF-related mortality rate (1.1 vs. 2.0%; p = 0.37), all-cause hospitalization rate (16.1 vs. 18.3%; p = 0.48), or mean change in percent FVC (-2.7 vs. -3.1%; p = 0.44). A relative, but not absolute, FVC decline of ≥10% favored AAT (15 vs. 22%; p = 0.03). Severe gastrointestinal AEs (3.7 vs. 0.9%; p = 0.015) and severe pulmonary infections (3.7 vs. 1.1%; p = 0.035) were more frequent with AAT. CONCLUSIONS:AAT and pirfenidone had outcomes comparable to those of pirfenidone alone in patients with IPF, underscoring the need for prospective trials to elucidate the role of AAT with or without antifibrotic drugs as a treatment for IPF.
Authors: Wim A Wuyts; Francesco Bonella; Ulrich Costabel; Vincent Cottin; Michael Kreuter; Venerino Poletti; Paolo Spagnolo Journal: Am J Respir Crit Care Med Date: 2016-02-01 Impact factor: 21.405
Authors: Joyce S Lee; Jay H Ryu; Brett M Elicker; Carmen P Lydell; Kirk D Jones; Paul J Wolters; Talmadge E King; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2011-06-23 Impact factor: 21.405
Authors: Marco G Patti; Pietro Tedesco; Jeffrey Golden; Steven Hays; Charles Hoopes; Adam Meneghetti; Tanuja Damani; Lawrence W Way Journal: J Gastrointest Surg Date: 2005-11 Impact factor: 3.452
Authors: Jason Abramowitz; Punam Thakkar; Arton Isa; Alan Truong; Connie Park; Richard M Rosenfeld Journal: Otolaryngol Head Neck Surg Date: 2016-05-17 Impact factor: 3.497
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Lisa Lancaster; David J Lederer; Jonathan A Leff; Steven D Nathan; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Talmadge E King Journal: Eur Respir J Date: 2015-12-02 Impact factor: 16.671
Authors: Prosenjit Dutta; Wendy Funston; Ian A Forrest; A John Simpson; Helen Mossop; Vicky Ryan; Rhys Jones; Rebecca Forbes; Shilpi Sen; Jeffrey Pearson; S Michael Griffin; Jaclyn A Smith; Christopher Ward Journal: Thorax Date: 2019-01-04 Impact factor: 9.102
Authors: Mauricio Gonzalez-Garcia; Emily Rincon-Alvarez; Maria Laura Alberti; Mauricio Duran; Fabian Caro; Maria Del Carmen Venero; Yuri Edison Liberato; Ivette Buendia-Roldan Journal: Front Med (Lausanne) Date: 2021-06-17
Authors: Helen E Jo; Tamera J Corte; Ian Glaspole; Christopher Grainge; Peter M A Hopkins; Yuben Moodley; Paul N Reynolds; Sally Chapman; E Haydn Walters; Christopher Zappala; Heather Allan; Gregory J Keir; Wendy A Cooper; Annabelle M Mahar; Samantha Ellis; Sacha Macansh; Nicole S Goh Journal: BMC Pulm Med Date: 2019-05-03 Impact factor: 3.317